JavaScript is not enabled. Please enable JavaScript to view the site properly.

You are now leaving Feraheme.com. AMAG Pharmaceuticals, Inc. is not responsible for the information contained in any of the linked third-party sites. Please review the site's Privacy Policy and Terms of Use, as AMAG's policies do not apply to third-party sites.

Only administer Feraheme as an intravenous infusion over at least 15 minutes and only when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions.

Observe for signs or symptoms of hypersensitivity reactions during and for at least 30 minutes following Feraheme infusion including monitoring of blood pressure and pulse during and after Feraheme administration.

Hypersensitivity reactions have occurred in patients in whom a previous Feraheme dose was tolerated.

Uninsured and underinsured patients with no other identified source of drug coverage may be eligible to receive FERAHEME at no cost. To apply, a patient must submit a patient enrollment form through his or her healthcare provider.

An AMAG Assist Care Manager typically is able to advise the patient and physician’s office on patient eligibility within 1 business day of receiving a completed application and supporting documentation. For their eligible patients, healthcare providers can schedule a shipment of FERAHEME. A copy of a valid physician’s state license must be received before FERAHEME can be delivered to the physician’s office.

Both you and your patient MUST sign the AMAG Assist Patient Enrollment Form

Fax to AMAG Assist at 844-635-AMAG (2624)

You will receive a faxed confirmation upon receipt

Verifying Insurance Through AMAG Assist

For patients who are insured, you will receive a detailed insurance coverage profile. For patients who are uninsured or functionally under-insured, eligibility for the Patient Assistance Program will be reviewed on an individualized basis.

AMAG Assist Care Managers are available to answer questions
about support services at 844-635-AMAG (2624) during its hours of
operation from Monday &dash; Friday, 8:00AM to 6:00PM ET.

Call 877-411-2510

To place an order

For questions about FERAHEME

To report an adverse event. If you prefer, you may contact the U.S. Food and Drug
Administration (FDA) directly at fda.gov/medwatch or call 1-800-FDA-1088

Only administer Feraheme as an intravenous infusion over at least 15 minutes and only when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions.

Observe for signs or symptoms of hypersensitivity reactions during and for at least 30 minutes following Feraheme infusion including monitoring of blood pressure and pulse during and after Feraheme administration.

Hypersensitivity reactions have occurred in patients in whom a previous Feraheme dose was tolerated.

Indication and Dosing

Feraheme is indicated for the treatment of iron deficiency anemia (IDA) in adult patients:

who have intolerance to oral iron or have had unsatisfactory response to oral iron or

who have chronic kidney disease (CKD)

The recommended dose of FERAHEME is an initial 510 mg dose followed by a second 510 mg dose as early as 3 days and up to 8 days later, each dose infused over at least 15 minutes while the patient is in a reclined or semi-reclined position.

Contraindications

Feraheme is contraindicated in patients with known hypersensitivity to Feraheme or any of its components or a history of allergic reaction to any intravenous iron product.

Warnings and Precautions

Hypersensitivity: In addition to the fatal and serious adverse reactions in the Boxed Warning, other adverse reactions associated with hypersensitivity have occurred (pruritus, rash, urticaria, and wheezing). Allergic reactions have occurred following the first dose or subsequent doses in patients in whom a previous dose was tolerated. Patients with a history of multiple drug allergies may have a greater risk of anaphylaxis with parenteral iron products. Carefully consider the potential risks and benefits before administering Feraheme to these patients. Elderly patients with multiple or serious co-morbidities who experience hypersensitivity reactions and/or hypotension following administration of Feraheme may have more severe outcomes.

Hypotension: Feraheme may cause clinically significant hypotension. Monitor patients for signs and symptoms of hypotension following each Feraheme administration.

Iron Overload: Excessive therapy with parenteral iron can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis. Regularly monitor the hematologic response during parenteral iron therapy. Do not administer Feraheme to patients with iron overload.

Magnetic Resonance (MR) Imaging Test Interference: Administration of Feraheme may transiently affect the diagnostic ability of MR imaging. Alteration of MR imaging studies may persist for up to 3 months following the last Feraheme dose. Maximum alteration of vascular MR imaging is anticipated to be evident for 1 – 2 days following Feraheme administration.

You may report an adverse event related to AMAG Pharmaceuticals’ products by calling 1-877-411-2510 or emailing amag@druginfo.com. If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly at fda.gov/medwatch or call 1-800-FDA-1088.